Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.58 |
| ▸ | RECQL | P46063 | 4/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577557 | 1.00 | KDM6B (0.60) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL30915529 | 1.00 | KDM6B (0.60) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL2321567 | 1.00 | KDM6B (0.60) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL22572803 | 0.87 | ALB (0.54) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL30724831 | 0.86 | KDM6B (0.64) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL5063603 | 0.85 | KDM6B (0.62) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL29669984 | 0.85 | KDM6B (0.62) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL29429645 | 0.85 | KDM6B (0.62) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL11575402 | 0.84 | KDM6B (0.57) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL11575407 | 0.84 | KDM6B (0.57) | KDM6BKDM4EHSD17B10TDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049409-A1 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2025-02-13 | — | — | US | claimed |
| CN-119907695-A | Novel small gastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy | 慕尼黑工业大学 | 2025-04-29 | — | — | CN | disclosed |
| US-20250049409-A1 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2025-02-13 | — | — | US | disclosed |
| US-20240059724-A1 | DEVICE AND CASSETTE FOR PERFORMING A PLURALITY OF SYNTHESIS PROCESSES OF PREPARING A RADIOPHARMACEUTICAL IN SERIES | OUT AND OUT CHEMISTRY S.P.R.L. (BE) | 2024-02-22 | — | — | US | disclosed |
| US-11820790-B2 | Device and cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series | OUT AND OUT CHEMISTRY S.P.R.L. (BE) | 2023-11-21 | — | — | US | disclosed |
| EP-4171592-A1 | METHODS FOR DERIVING DOPAMINERGIC NEURONS FROM PLURIPOTENT STEM CELLS | Minerva Biotechnologies Corporation (US) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021263241-A1 | METHODS FOR DERIVING DOPAMINERGIC NEURONS FROM PLURIPOTENT STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3917944-A1 | THERAPEUTIC PEPTIDES | Cohbar Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210322463-A1 | METHOD FOR ACCELERATED TISSUE PENETRATION OF COMPOUNDS INTO BRAIN | LIKEMINDS INC (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3823679-A1 | METHOD FOR ACCELERATED TISSUE PENETRATION OF COMPOUNDS INTO BRAIN | Likeminds, Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2016184980-A1 | METHOD OF PERFORMING A PLURALITY OF SYNTHESIS PROCESSES OF PREPARING A RADIOPHARMACEUTICAL IN SERIES, A DEVICE AND CASSETTE FOR PERFORMING THIS METHOD | OUT AND OUT CHEMISTRY S.P.R.L. (BE) | 2016-11-24 | — | — | WO | disclosed |
| EP-2785445-A1 | PRODUCTION OF 18F- LABELLED COMPOUNDS COMPRISING HYDROLYTIC DEPROTECTION STEP AND SOLID PHASE EXTRACTION | GE Healthcare UK Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8722014-B2 | 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof | WASHINGTON UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2013079578-A1 | PRODUCTION OF 18F- LABELLED COMPOUNDS COMPRISING HYDROLYTIC DEPROTECTION STEP AND SOLID PHASE EXTRACTION | GE HEALTHCARE LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| US-20100278732-A1 | 1H-[1, 2, 3] TRIAZOLE SUBSTITUTED AMINO ACIDS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2101768-A2 | USE OF NEUROPROTECTIVE COMPOUNDS FOR OBTAINING DRUGS FOR TREATING NEURODEGENERATIVE DISEASES | Les Laboratoires Servier (FR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008099083-A2 | USE OF NEUROPROTECTIVE COMPOUNDS FOR OBTAINING DRUGS FOR TREATING NEURODEGENERATIVE DISEASES | LES LABORATOIRES SERVIER (FR) | 2008-08-21 | — | — | WO | disclosed |
| EP-1797029-A1 | METHOD OF DEPROTECTION | GE Healthcare Limited (GB) | 2007-06-20 | — | — | EP | disclosed |
| CN-1894173-A | Preparation of 18-fluoro-labeled aromatic amino acids | UNIV EBERHARD KARLS (DE) | 2007-01-10 | — | — | CN | disclosed |
| WO-2006037950-A1 | METHOD OF DEPROTECTION | GE HEALTHCARE LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278732-A1 | 1H-[1, 2, 3] TRIAZOLE SUBSTITUTED AMINO ACIDS AND USES THEREOF | SLC7A1, SLC1A5, SLC1A3 | KDM6B 4699/4885KDM4E 4738/4885HSD17B10 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.